Diabetes: Epidemiology, Pathophysiology and Clinical Management aims to be the one-stop diabetes book for researchers, scientists and clinicians. It details the epidemiology, causes, molecular mechanisms, molecular markers, available drugs, experimental drugs, treatment modalities, and dietary and lifestyle approaches related to diabetes. It focuses on various molecular aspects of diabetes, and its related co-morbidities. Apart from the drug-based treatment approach based on international guidelines, this book also describes various surgical treatments available for cases of uncontrolled symptomatic diabetes. It also lays emphasis on the future possibilities of different approaches for diabetes management.
Key Features
Includes treatment guidelines and approaches to diabetes provided by major global diabetes associationsProvides a thorough and comprehensive assimilation of detailed information and updates in the field of diabetes, helpful for researchers, scientists and cliniciansContains a chapter on anti-diabetic drugs, that covers both the commercially approved drugs as well as those that are in various phases of experimental, pre-clinical, and clinical trials
Recenzijas
"One of the main strengths of this book is its size. Including the index, the book runs to just 132 pages but I dont see this as a weakness. In fact, it is a strength of this book at it means that it is quite feasible to read the book from cover to cover without too much difficulty. This is a huge bonus as despite its slim dimensions, it packs in a lot of data in an easy-to-read format.
All in all, there is a lot of fascinating information here which gives a rounded and grounded tour of diabetes in a slim volume. Great credit to the authors who have produced this clever and informative book in a very readable format. Big is not necessarily beautiful and a busy clinician can easily read this whole book in a relatively short space of time and as a result be well acquainted with modern thinking in diabetes."
--Dr Harry Brown, June 2021
| Important Caveat |
|
ix | |
| Preface |
|
xi | |
| Acknowledgements |
|
xiii | |
| Authors |
|
xv | |
| Abbreviations |
|
xvii | |
|
Chapter 1 Diabetes Epidemiology - 1980 and Beyond |
|
|
1 | (6) |
|
Face-to-Face with the Global Diabetes Epidemiology |
|
|
1 | (5) |
|
|
|
6 | (1) |
|
Chapter 2 Diabetes and Inflammation |
|
|
7 | (10) |
|
|
|
7 | (1) |
|
General Mechanism of Inflammation-Induced Insulin Resistance |
|
|
8 | (2) |
|
Macrophage Activation and Insulin Resistance in Obesity |
|
|
8 | (2) |
|
Role of Pro-Inflammatory Cytokines in Diabetes |
|
|
10 | (4) |
|
Tumour Necrosis Factor - α |
|
|
10 | (1) |
|
|
|
10 | (1) |
|
C - Reactive Protein (CRP) |
|
|
11 | (1) |
|
|
|
12 | (2) |
|
|
|
14 | (1) |
|
|
|
15 | (2) |
|
Chapter 3 Insulin Resistance and Glucose Regulation |
|
|
17 | (18) |
|
Introduction to Insulin Resistance |
|
|
17 | (3) |
|
Obesity as a Cause of Insulin Resistance |
|
|
20 | (6) |
|
|
|
20 | (1) |
|
|
|
21 | (1) |
|
|
|
22 | (1) |
|
Resistin and lnterleukin-α |
|
|
23 | (1) |
|
|
|
24 | (2) |
|
Fibroblast Growth Factor 21 |
|
|
26 | (1) |
|
Dietary Effect on Insulin Resistance |
|
|
27 | (3) |
|
Fatty Acid Mediated Insulin Resistance |
|
|
27 | (1) |
|
Fructose-Induced Insulin Resistance |
|
|
28 | (2) |
|
|
|
30 | (1) |
|
|
|
30 | (5) |
|
Chapter 4 Diabetes: A Leading Contributor to Other Disease Complications |
|
|
35 | (18) |
|
|
|
35 | (2) |
|
|
|
37 | (1) |
|
Diabetes-Related Complications |
|
|
38 | (7) |
|
|
|
38 | (2) |
|
|
|
40 | (1) |
|
|
|
40 | (1) |
|
|
|
41 | (1) |
|
|
|
42 | (1) |
|
|
|
43 | (2) |
|
|
|
45 | (3) |
|
|
|
45 | (1) |
|
Genito-Urinary Infections |
|
|
45 | (1) |
|
|
|
45 | (1) |
|
|
|
46 | (2) |
|
|
|
48 | (1) |
|
|
|
48 | (5) |
|
Chapter 5 Biomarkers of Diabetes |
|
|
53 | (20) |
|
|
|
53 | (1) |
|
|
|
54 | (3) |
|
|
|
57 | (10) |
|
Glycated Haemoglobin (HbA1c) |
|
|
57 | (4) |
|
1,5-Anhydroglucitol (1,5-AG) |
|
|
61 | (1) |
|
|
|
62 | (3) |
|
|
|
65 | (2) |
|
Skin and Lens Autofluorescence |
|
|
67 | (1) |
|
|
|
67 | (6) |
|
Chapter 6 Anti-Diabetic Drugs |
|
|
73 | (22) |
|
|
|
73 | (2) |
|
Parenteral Anti-Diabetic Drugs (Insulin) |
|
|
75 | (2) |
|
|
|
77 | (4) |
|
Drugs for Diabetes Insipidus |
|
|
81 | (1) |
|
Drugs from the Labs: The Story of Possibilities |
|
|
82 | (7) |
|
|
|
82 | (1) |
|
|
|
83 | (3) |
|
|
|
86 | (2) |
|
|
|
88 | (1) |
|
|
|
89 | (6) |
|
Chapter 7 Diagnosis and Treatment |
|
|
95 | (16) |
|
|
|
95 | (3) |
|
Pharmacological Treatment of Diabetes |
|
|
98 | (2) |
|
Surgical Treatment of Diabetes |
|
|
100 | (7) |
|
|
|
107 | (4) |
|
Chapter 8 Dietary and Lifestyle Management of Diabetes |
|
|
111 | (12) |
|
Importance of Dietary and Lifestyle Management in Diabetes |
|
|
111 | (9) |
|
Metabolic Effects of Exercise |
|
|
114 | (4) |
|
Gut Microbiome and Diabetes: Old Companion with a New Angle |
|
|
118 | (2) |
|
|
|
120 | (3) |
|
Chapter 9 Future Prospects and Recommendations |
|
|
123 | (2) |
| Index |
|
125 | |
Dr. Awanish Kumar
Presently Dr. Awanish Kumar is working as an Assistant Professor in the Department of Biotechnology, National Institute of Technology, Raipur, India. He has more than 10 years of post Ph.D. research experience in the area of drug discovery and health care. He has obtained his Ph.D. degree from Central Drug Research Institute (CDRI), Lucknow & Jawaharlal Nehru University (JNU), New Delhi, India in 2009. He has done post doctoral study from McGill University, Canada. Dr. Kumar has served various national and international organizations with different academic/research capacities. He has published more than 100 peer reviewed research paper in SCI journals. He is the author of several books and chapters. Currently, he is serving various national institutional committees, scientific society, advisory panel and giving his active contribution in academic and research. Awards and laurels won by Dr. Kumar run into volumes. He is the member of many international professional research societies and reviewer/editorial board member of reputed and refereed journals.
Dr. Ashwini Kumar
Dr. Ashwini Kumar did his M.Tech (Biotechnology) from Department of Biotechnology & Medical Engineering, National Institute of Technology Rourkela (Odisha), India. His masters research was focused on obesity checking the effect of flavonoids on the lipid accumulation in adipocytes. He did his PhD under the supervision of Dr. Awanish Kumar from the Department of Biotechnology, National Institute of Technology Raipur (Chhattisgarh), India. The broad area of his doctoral research was formulation of mucoadhesive drug delivery systems. His interest lies in biomaterials and metabolic diseases. He has 14 journal publications and 7 book chapters to his credit. Currently, he is working as a Research Associate in Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, India.
